OMPDC

OMPDC (PF3D7_1023200) catalyzes the decarboxylation of orotidine 5'-monophosphate (OMP) to uridine 5'-monophosphate (UMP), the terminal step of de novo pyrimidine biosynthesis in P. falciparum, an activity first detected in parasite extracts (PMID:6285190). Recombinant PfOMPDC is catalytically active as a homodimer (38 kDa subunit) and adopts a TIM-barrel fold with flexible phosphate-binding and βα5 loops, binding OMP with sub-micromolar affinity (PMID:15683248, PMID:18303855); crystal structures in apo, substrate-, and product-bound states show that substrate recognition proceeds through dynamic rearrangement of the active-site hydrogen-bond array and movement of the L1/L2 loops (PMID:17981823, PMID:22740703). In P. falciparum the enzyme does not act alone but assembles with orotate phosphoribosyltransferase (PfOPRT) into a ~140 kDa heterotetrameric (PfOPRT)2(PfOMPDC)2 multienzyme complex, verified by co-purification and chemical cross-linking (PMID:15147974, PMID:15683248), with the interaction mediated by unique low-complexity insertion sequences at the α2 and α5 helices of PfOMPDC that are absent from homologs in other organisms (PMID:24507637). Complex formation is functionally consequential, conferring up to 125-fold higher catalytic efficiency and increased thermal stability relative to the monofunctional enzyme (PMID:19800871), a gain recapitulated by an engineered OMPDC–OPRT gene fusion (PMID:28389349). The active site is competitively inhibited by nucleoside 5'-monophosphate analogues including pyrazofurin-5'-monophosphate and XMP with nanomolar affinity, with XMP substantially more potent against the parasite than the human enzyme, marking OMPDC as a drugable antimalarial target (PMID:18303855, PMID:20813141).

1. 1982 Medium

   Establishing whether the malaria parasite carries de novo pyrimidine synthesis machinery answered whether OMPDC activity is present at all, defining the pathway as an intrinsic parasite capability.

   Evidence OMPDC enzymatic activity assay in P. falciparum trophozoite cell-free extracts

   PMID:6277049 PMID:6285190

   Open questions at the time

   • Activity in crude extract does not identify the responsible gene or protein
   • No purified enzyme or kinetic parameters
2. 1986 Low

   Testing pyrazofurin against parasite OMPDC activity answered whether the enzyme is pharmacologically inhibitable, first pointing to its therapeutic potential.

   Evidence Enzymatic inhibition assay with pyrazofurin 5'-monophosphate in parasite extracts

   PMID:3515174

   Open questions at the time

   • Inhibition measured in crude extract, not on purified enzyme
   • No affinity or mechanism of inhibition determined
3. 2005 High

   Cloning and reconstituting recombinant PfOMPDC answered what the isolated gene product is and how it differs from the parasite complex, showing it is an active homodimer whose kinetics diverge from the native heterotetramer.

   Evidence cDNA cloning, E. coli expression, kinetics, chemical cross-linking (dimethyl suberimidate), and inhibitor profiling

   PMID:15683248

   Open questions at the time

   • Structural basis of homodimer/heterotetramer distinction not yet resolved
   • In vivo essentiality not tested
4. 2007 High

   Solving apo, substrate-, and product-bound crystal structures answered how the active site recognizes substrate, revealing dynamic hydrogen-bond rearrangement upon ligand binding.

   Evidence X-ray crystallography of three ligand states of recombinant PfOMPDC

   PMID:16754976 PMID:17981823

   Open questions at the time

   • Catalytic mechanism of decarboxylation not dissected by mutagenesis
   • Structures of the full heterotetrameric complex not obtained
5. 2008 High

   Systematic kinetic and inhibitor characterization with structure answered how tightly and by what mechanism nucleotide analogues bind, defining nanomolar competitive inhibitors with parasite-versus-human selectivity.

   Evidence Recombinant enzyme kinetics, competitive inhibition assays with multiple analogues, X-ray structure, and covalent inhibitor SAR

   PMID:18189347 PMID:18303855

   Open questions at the time

   • Cellular efficacy of inhibitors against live parasites not established
   • Selectivity for parasite complex over monofunctional forms not addressed
6. 2009 Medium

   Reconstituting the recombinant OPRT-OMPDC complex answered whether physical association changes enzyme performance, showing large gains in catalytic efficiency and thermal stability over the monofunctional enzyme.

   Evidence Recombinant co-purification, kinetics, thermal inactivation, and pyrophosphate inhibition assays

   PMID:19800871

   Open questions at the time

   • Physiological trigger and stoichiometry of assembly in the parasite not defined
   • Contribution of each subunit to the efficiency gain not separated
7. 2014 Medium

   Mapping the interaction interface answered how the parasite-specific complex assembles, attributing OPRT binding to unique low-complexity insertions at the OMPDC α2 and α5 helices absent from other organisms.

   Evidence Bifunctional chemical cross-linking with LC-MS and homology modeling

   PMID:24507637

   Open questions at the time

   • Interface residues not validated by mutagenesis
   • No co-crystal structure of the interface
8. 2018 Medium

   Re-refining earlier structures answered whether the deposited Michaelis complex correctly modeled substrate, correcting the identity of the bound ligand from OMP to the product UMP.

   Evidence Crystallographic re-refinement of PDB entries 2za1/2za2/2za3

   PMID:30279319

   Open questions at the time

   • A true substrate-bound Michaelis complex remains structurally uncharacterized
   • No new functional data generated

• Whether OMPDC is essential for parasite survival in vivo and whether its inhibitors kill live parasites remain unresolved.
• No genetic knockout or conditional depletion in P. falciparum reported
• No demonstrated antiparasitic activity of the characterized inhibitors in cell-based or animal models
• Mutagenesis validation of catalytic and interface residues absent